Latest From Endotis Pharma
The French Society of Medicinal Chemistry has awarded its 2009 Charles Mentzer Prize to Dr Maurice Petitou.
Despite continuing pharmacological and physiological advances, ongoing public health campaigns, and well established guidelines defining challenging treatment targets, cardiovascular disease (CVD) kills more people globally than any other disease. Nevertheless, the pharmaceutical industry seems divided over whether CVD still holds the prospect of realising a reasonable return on investment. On the one hand, several companies are pulling out of CVD R&D, despite having a rich cardiovascular heritage. For example, Pfizer and Wyeth, currently mid-merger, individually announced a shift in focus away from cardiology towards areas such as oncology and neurology.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Endotis Pharma
- Senior Management
Charles Woler, MD, Chmn. & CEO
Maurice Petitou, PhD, Head, Preclinical R&D
Eric Neuhart, MD, Head, Clinical R&D
Stephane Degove, Head, Fin.
- Contact Info
Phone: (33) 148 46 43 91
Parc Biocitech , 102 route de Noisy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.